Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Evaluation of Tracers for Positron Emission Tomography (PET) Imaging of Tau

Start: August 2014
End: February 2016
Enrollment: 34

What Is This Study About?

This study is designed to obtain basic information about three PET imaging tracers developed to detect tau pathology in the brain. Abnormal tau is part of neurofibrillary tangles found in the brain of people with Alzheimer's. Healthy participants (controls) 25-40 or 50-80 years old and participants with Alzheimer's disease 50-80 years old may participate.

Do I Qualify To Participate in This Study?

Minimum Age: 25 Years

Maximum Age: 80 Years

Must have:

All Participants

  • Agreement to use highly effective contraception measures
  • If taking a medication, should be on stable dose for at least 4 weeks prior to start of study
  • Body mass index (BMI) of 18-32
  • Weight of 300 pounds or less

Healthy Controls

  • Age 25-40 years or 50-80 years
  • Normal cognitive function, including a normal Mini-Mental State Examination (MMSE) score
  • Healthy control participants who receive the tracer [11C]RO6924963 must be less than 6'5" tall

Participants with Alzheimer's Disease

  • Diagnosis of probable Alzheimer's disease, according to the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria
  • Age 50-80 years
  • Capacity for informed consent
  • MMSE score between 16 and 26, inclusive

Must NOT have:

  • History or presence of a neurological diagnosis other than Alzheimer's that may influence the outcome or analysis of the brain scan results; may include but is not limited to stroke, traumatic brain injury, space occupying lesions, non-Alzheimer's tauopathies, and Parkinson's disease
  • Medical history that includes known autosomal dominant Alzheimer's mutations in amyloid precursor protein (APP) or presenilin (PS1, PS2) or mutations in genes that cause other types of autosomal dominant familial dementia
  • History or presence of any clinically relevant hematological, hepatic, respiratory, cardiovascular, renal, metabolic, endocrine, or central nervous system disease
  • Other medical conditions that are not well controlled, may put the subject at risk, could interfere with the objectives of the study, or make the subject unsuitable for participation in the study
  • Clinically relevant pathological findings in physical examination, electrocardiogram, or laboratory values at the screening assessment that could interfere with the objectives of the study
  • Known history of clinically significant infectious disease such as AIDS; indication of acute/chronic hepatitis B, hepatitis C, or HIV infection
  • Pregnancy or lactation
  • Unsuitable veins for repeated venipuncture
  • History of drug allergy or hypersensitivity
  • Alcohol consumption that averages more than three drinks daily
  • Regular smoker (more than 10 cigarettes, three pipefuls, or three cigars per day)
  • Coffee or tea consumption of more than 10 cups per day or methylxanthine-containing drinks of more than 1.5 L/day
  • Has received an investigational medication within the last 3 months or 5 times the elimination half-life, whichever is longer, prior to enrollment
  • Presence of any medical device or circumstance (such as claustrophobia) that would contraindicate a magnetic resonance imaging scan
  • For participants who receive the tracers [11C]RO6924963 or [11C]RO6924963, any contraindications to arterial cannulation
  • Participants with probable Alzheimer's disease: Treatment targeting amyloid-beta or tau within the last 24 months

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Hoffmann-La Roche

Collaborator Sponsor

  • Johns Hopkins University

Source: ClinicalTrials.gov ID: NCT02187627

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health